Testing the Use of Fulvestrant and Binimetinib Targeted Treatment for NF1 Mutation in Hormone Receptor-Positive Metastatic Breast Cancer, A ComboMATCH Treatment Trial
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Anatomic Stage IV Breast Cancer AJCC v8|Metastatic HER2-Negative Breast Carcinoma|Metastatic Hormone Receptor-Positive Breast Carcinoma
Interventions: DRUG: Binimetinib|PROCEDURE: Biopsy|PROCEDURE: Bone Scan|PROCEDURE: Computed Tomography|DRUG: Fulvestrant|PROCEDURE: Magnetic Resonance Imaging
Sponsor: National Cancer Institute (NCI)
Collaborators: NRG Oncology